Zhejiang Xianju Pharmaceutical Co.,Ltd. (SHE:002332)
China · Delayed Price · Currency is CNY 8.81
+0.04 (0.46%)
Apr 29, 2026, 3:04 PM CST
SHE:002332 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,669 | 3,759 | 3,980 | 4,079 | 4,358 | 4,335 |
Other Revenue | - | - | 21.17 | 43.96 | 21.52 | 22.46 |
| 3,669 | 3,759 | 4,001 | 4,123 | 4,380 | 4,357 | |
Revenue Growth (YoY) | -7.60% | -6.04% | -2.98% | -5.85% | 0.52% | 8.42% |
Cost of Revenue | 1,381 | 1,459 | 1,744 | 1,972 | 1,865 | 1,848 |
Gross Profit | 2,288 | 2,300 | 2,256 | 2,152 | 2,515 | 2,509 |
Selling, General & Admin | 1,538 | 1,498 | 1,344 | 1,271 | 1,532 | 1,560 |
Research & Development | 301.98 | 303.75 | 265.17 | 261 | 266.77 | 243.37 |
Other Operating Expenses | 2.96 | 8.3 | 19.26 | 22.04 | 32.92 | 32.73 |
Operating Expenses | 1,843 | 1,810 | 1,639 | 1,547 | 1,836 | 1,836 |
Operating Income | 445.31 | 490.12 | 617.42 | 604.79 | 678.81 | 672.92 |
Interest Expense | - | - | -3.13 | -3.37 | -6.29 | -23.1 |
Interest & Investment Income | - | - | 29.48 | 38.28 | 76.54 | 43.19 |
Currency Exchange Gain (Loss) | - | - | 10.57 | -9.32 | 11.8 | 17.44 |
Other Non Operating Income (Expenses) | 59.19 | 64.04 | -2.7 | -5.53 | -11.25 | -5.26 |
EBT Excluding Unusual Items | 510.28 | 554.17 | 651.63 | 624.85 | 749.6 | 705.19 |
Gain (Loss) on Sale of Investments | -31.98 | -26.41 | -8.14 | -8.97 | -0 | 0.64 |
Gain (Loss) on Sale of Assets | 46.18 | 46.3 | 0.28 | -1.48 | 91.62 | 14.51 |
Asset Writedown | -38.21 | -38.21 | -1.31 | -0.42 | -0.91 | -1.68 |
Other Unusual Items | - | - | -170.81 | 27.7 | 31.58 | 11.2 |
Pretax Income | 486.26 | 535.84 | 498.33 | 641.68 | 871.89 | 729.87 |
Income Tax Expense | 81.46 | 83.24 | 98.4 | 79.56 | 124.49 | 108.6 |
Earnings From Continuing Operations | 404.81 | 452.6 | 399.92 | 562.12 | 747.4 | 621.26 |
Minority Interest in Earnings | -5.27 | -2.96 | -2.74 | 0.97 | 2.01 | -1.94 |
Net Income | 399.54 | 449.64 | 397.18 | 563.08 | 749.41 | 619.33 |
Net Income to Common | 399.54 | 449.64 | 397.18 | 563.08 | 749.41 | 619.33 |
Net Income Growth | 2.44% | 13.21% | -29.46% | -24.86% | 21.00% | 22.76% |
Shares Outstanding (Basic) | 999 | 999 | 993 | 988 | 989 | 989 |
Shares Outstanding (Diluted) | 999 | 999 | 993 | 988 | 989 | 989 |
Shares Change (YoY) | 0.64% | 0.63% | 0.51% | -0.13% | 0.00% | 7.84% |
EPS (Basic) | 0.40 | 0.45 | 0.40 | 0.57 | 0.76 | 0.63 |
EPS (Diluted) | 0.40 | 0.45 | 0.40 | 0.57 | 0.76 | 0.63 |
EPS Growth | 1.78% | 12.50% | -29.83% | -24.76% | 21.00% | 13.84% |
Free Cash Flow | 181.24 | 38.4 | 191.07 | 360.85 | 326.74 | 409.31 |
Free Cash Flow Per Share | 0.18 | 0.04 | 0.19 | 0.36 | 0.33 | 0.41 |
Dividend Per Share | - | - | 0.300 | 0.300 | 0.300 | 0.150 |
Dividend Growth | - | - | - | - | 100.00% | - |
Gross Margin | 62.36% | 61.19% | 56.40% | 52.18% | 57.42% | 57.58% |
Operating Margin | 12.14% | 13.04% | 15.43% | 14.67% | 15.50% | 15.44% |
Profit Margin | 10.89% | 11.96% | 9.93% | 13.66% | 17.11% | 14.21% |
Free Cash Flow Margin | 4.94% | 1.02% | 4.78% | 8.75% | 7.46% | 9.39% |
EBITDA | 663.17 | 707.98 | 835.24 | 816.24 | 866.26 | 857.11 |
EBITDA Margin | 18.07% | 18.83% | 20.88% | 19.79% | 19.78% | 19.67% |
D&A For EBITDA | 217.86 | 217.85 | 217.82 | 211.45 | 187.46 | 184.19 |
EBIT | 445.31 | 490.12 | 617.42 | 604.79 | 678.81 | 672.92 |
EBIT Margin | 12.14% | 13.04% | 15.43% | 14.67% | 15.50% | 15.44% |
Effective Tax Rate | 16.75% | 15.53% | 19.75% | 12.40% | 14.28% | 14.88% |
Revenue as Reported | - | - | 4,001 | 4,123 | 4,380 | 4,357 |
Advertising Expenses | - | - | 712.54 | 685.06 | 991.03 | 1,035 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.